
Jasper Therapeutics Investor Relations Material
Latest events

Study Update
Jasper Therapeutics

Q1 2025
12 May, 2025

Q4 2024
27 Feb, 2025
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Jasper Therapeutics Inc
Access all reports
Jasper Therapeutics, Inc. is a clinical-stage biotechnology company specializing in the development of therapeutic agents primarily for hematopoietic stem cell transplantation and gene therapies. The company is focused on advancing novel therapeutic agents intended for a variety of applications, including conditions like chronic spontaneous urticaria and lower to intermediate risk myelodysplastic syndromes. Additionally, Jasper Therapeutics is developing new conditioning regimens for stem cell transplantation and ex-vivo gene therapy, which involves the genetic manipulation of cells outside the body before transplantation. Their leading product candidate, briquilimab, is designed to clear hematopoietic stem cells from bone marrow to facilitate allogeneic stem cell or gene therapy. The company is headquartered in Redwood City, California, and its shares are listed on the NASDAQ.
Key slides for Jasper Therapeutics Inc


Study Result
Jasper Therapeutics Inc


Corporate Presentation
Jasper Therapeutics Inc
Latest articles
)
Airbnb: The Hospitality Giant Without Property
Airbnb has grown from an idea to help the Co-Founders make rent, to one of the most dominant companies in the global hospitality industry.
13 Jun 2025
)
MSCI: Indexing the World
The story of how MSCI has become the backbone of global finance through its indexes, powering decision-making across trillions in assets.
30 May 2025
)
A Purpose-Built AI Chat for Finance and IR Professionals
Quartr Pro's new AI chat lets IR and finance professionals ask anything across 13,000+ public companies and get instant answers.
27 May 2025
Ticker symbol
JSPR
Country
🇺🇸 United States